

Trend Macrolytics, LLC Donald Luskin, Chief Investment Officer Thomas Demas, Managing Director Michael Warren, Energy Strategist

0%

Mar '22

#### Data Insights: Covid-2019 Monitor

Tuesday, March 22, 2022



#### For more information contact us: Donald Luskin: 214 550 2121 <u>don@trendmacro.com</u> Thomas Demas: 704 552 3625 tdemas@trendmacro.com

Source: Johns Hopkins, TrendMacro calculations

Jan '20

Mar '20 May '20 Jul '20 Sep '20 Nov '20

Copyright 2022 Trend Macrolytics LLC. All rights reserved. This document is not to be forwarded to individuals or organizations not authorized by Trend Macrolytics LLC to receive it. For information purposes only; not to be deemed to be recommendations for buying or selling specific securities or to constitute personalized investment advice. Derived from sources deemed to be reliable, but no warranty is made as to accuracy.

Jan '21

Mar '21

May '21

Jul '21

Sep '21

Nov '21

Jan '22



Source: Johns Hopkins, Dept. of Health and Human Services, CDC, TrendMacro calculations

| Rolling out the vaccines in the US and the world |       |                           |             |          |       |            |                |                  |          |                    |                   |           |
|--------------------------------------------------|-------|---------------------------|-------------|----------|-------|------------|----------------|------------------|----------|--------------------|-------------------|-----------|
| Administered Cumulative                          |       |                           |             |          |       |            | То             | day              | Immunity | Full               | Partial           |           |
| Doses 573,699,17                                 |       | 73,699,178                |             |          |       |            | +0.067         | million          | US       | 65.4%              | 76.8%             |           |
| Boosters                                         |       | 97,939,450                |             |          |       |            | +0.029 million |                  | UK       | 72.2%              | 77.3%             |           |
| 0                                                |       | One                       | dose        | % Pop Ir |       | nune       | % рор          | New immune today |          | France             | 77.8%             | 80.1%     |
| Total population                                 |       | 26                        | 262,676,768 |          | 22    | 23,327,830 | 67%            | +0.017 million   |          | Spain              | 85.5%             | 88.0%     |
| Age 12 to 17                                     |       | 17,485,573                |             | 69%      |       | 14,912,206 |                | +0.002 million   |          | Germany            | 75.1%             | 75.8%     |
| Age 18 to 64                                     |       | 176,981,436               |             | 87%      | 1     | 50,083,411 | 74%            | +0.009 million   |          | Italy              | 79.1%             | 84.0%     |
| Age 65 and over                                  |       | 58,292,080                |             | 100%     |       | 50,451,703 | 92%            | +0.001 million   |          | Australia          | 81.3%             | 86.0%     |
| ۲%۱                                              |       |                           |             |          |       |            |                |                  |          | Israel             | 65.9%             | 72.1%     |
| 3%                                               |       |                           |             | _        |       |            |                |                  |          | Canada             | 81.7%             | 85.8%     |
| Moderna<br>38%                                   |       | State                     |             | Bost     |       |            |                |                  |          | Japan              | 79.7%             | 81.0%     |
|                                                  |       |                           |             | Dest     |       |            |                |                  |          | Africa             | 14.9%             | 20.1%     |
|                                                  |       | At least partial immunity |             | Midd     | le.   |            |                |                  |          | India              | 58.8%             | 69.7%     |
|                                                  | 59%   | as % population           |             | IVIIUU   | 18    |            |                |                  |          | Brazil             | 74.2%             | 84.3%     |
|                                                  |       | Full immunity             |             | Moret    |       |            |                |                  | China    | 85.8%              | 88.1%             |           |
| AK<br>69.1%<br>61.5%                             |       | as % population           |             | vv ors   | st    |            | -              |                  |          | Global data differ | rs due to sources | s, timing |
|                                                  |       | "Immunity" = two doses    |             | WI       |       |            | As of Mar 21   |                  |          | ME                 |                   |           |
|                                                  |       |                           |             |          |       | 71.3%      |                |                  |          |                    | 89.3%             |           |
|                                                  |       |                           |             |          |       | 64.9%      |                | _                |          |                    | 78.7%             |           |
|                                                  | WA    | ID                        | MT          | ND       | MN    | IL         | MI             |                  | NY       | VT                 | NH                |           |
|                                                  | 80.1% | 60.6%                     | 64.7%       | 64.6%    | 74.6% | 76.3%      | 66.5%          |                  | 89.4%    | 92.8%              | 95.0%             |           |
|                                                  | 71.9% | 53.5%                     | 56.2%       | 54.6%    | 68.6% | 68.0%      | 59.6%          |                  | 76.0%    | 80.5%              | 69.5%             |           |
|                                                  | OR    | NV                        | WY          | SD       | IA    | IN         | OH             | PA               | NJ       | MA                 |                   | -         |
|                                                  | 77.3% | 74.5%                     | 58.2%       | 75.4%    | 67.5% | 61.0%      | 63.1%          | 83.8%            | 89.5%    | 95.0%              |                   |           |
|                                                  | 69.0% | 60.1%                     | 50.9%       | 60.3%    | 61.4% | 54.4%      | 57.9%          | 67.4%            | 74.8%    | 78.0%              |                   |           |
|                                                  | CA    | UT                        | CO          | NE       | MO    | KY         | WV             | VA               | MD       | CT                 | RI                |           |
|                                                  | 82.3% | 71.5%                     | 78.7%       | 69.6%    | 65.7% | 65.6%      | 64.5%          | 84.9%            | 85.4%    | 94.4%              | 95.0%             |           |
|                                                  | 71.0% | 63.6%                     | 69.6%       | 62.8%    | 55.5% | 56.9%      | 57.1%          | 72.4%            | 74.5%    | 78.2%              | 81.3%             |           |
|                                                  |       | AZ                        | NM          | KS       | AR    | TN         | NC             | SC               | DC       | DE                 |                   |           |
|                                                  |       | 72.0%                     | 86.5%       | 73.9%    | 66.1% | 61.6%      | 82.9%          | 67.0%            | 95.0%    | 82.2%              |                   |           |
|                                                  |       | 60.6%                     | 70.1%       | 60.7%    | 53.9% | 53.9%      | 59.7%          | 56.4%            | 72.2%    | 68.1%              |                   |           |
|                                                  |       |                           |             | OK       | LA    | MS         | AL             | GA               |          |                    |                   |           |
|                                                  |       |                           |             | 70.3%    | 60.6% | 59.1%      | 62.2%          | 64.7%            |          |                    |                   |           |
| HI<br>86.8%<br>77.7%                             |       |                           |             | 56.4%    | 53.0% | 51.3%      | 50.6%          | 54.1%            |          |                    |                   |           |
|                                                  |       |                           |             | TX       |       |            |                |                  | FL       |                    | PR                |           |
|                                                  |       |                           | 71.8%       |          |       |            |                | 78.5%            |          | 95.0%              |                   |           |
|                                                  |       |                           |             | 60.6%    |       |            |                |                  | 66.3%    | l l                | 82.0%             |           |
|                                                  |       |                           |             |          |       |            |                |                  |          | -                  |                   |           |

#### The demographics of US vaccination























Source: Johns Hopkins, Covid Act Now, TrendMacro calculations

National and state-by-state data do not line up because of different sources



Source: Distributions <u>CDC</u>, Comorbidities <u>CDC</u>, TrendMacro calculations

### Recommended reading

<u>Neuropsychopharmacology (NPP) 2020 report on</u> <u>gender balance among corresponding authors and</u> <u>reviewers: before and during the COVID-19 pandemic</u> Sofiya Hupalo *Neuropsychopharmacology* February 21, 2022

High Death Rate in Hong Kong Shows Importance of Vaccinating the Elderly

Benjamin Mueller *New York Times* March 21, 2022

#### <u>'He Goes Where the Fire Is': A Virus Hunter in the</u> <u>Wuhan Market</u>

Carl Zimmer *New York Times* March 21, 2022

<u>CDC reports fewer COVID-19 pediatric deaths after</u> <u>data correction</u>

*Reuters* March 18, 2022

## Meme of the day

# How should you talk to friends and relatives who believe conspiracy theories?



Source: Our beloved clients, Power Line blog "The Week in Pictures" and CTUP



The coronavirus <u>case</u> accelerometer... tracking the world's infection curves *Share of infected population from first day with 100 confirmed cases, log scale* 



# The coronavirus <u>mortality</u> accelerometer ... tracking the world's fatality curves *Share of deceased population from day of first fatality, log scale*





Source: Johns Hopkins, TrendMacro calculations



Source: Covid Act Now, TrendMacro calculations

From Ground Zero to the Rio Grande

Cases: 7-day average and daily Deaths: Daily



Source: Johns Hopkins, TrendMacro calculations





Patient zero... and then everyone else

Cases: 7-day average and daily Deaths: Daily

Source: Johns Hopkins, TrendMacro calculations



Source: Johns Hopkins, TrendMacro calculations

 Impact in The Anglosphere
 Cases: 7-day average and daily
 Deaths: Daily

 250,000
 United Kingdom
 18%

 200,000
 3071.45 bp of population infected
 16%

 24.65 bp of population fatalities
 14%







#### Impact in other hot-spots Cases: 7-day average and daily Deaths: Daily

Impact in the BRICs ex-China Cases: 7-day average and daily Deaths: Daily



Impact in the Middle East and Africa

Cases: 7-day average and daily Deaths: Daily



Impact in Africa, continued Cases: 7-day average and daily Deaths: Daily



Source: Johns Hopkins, TrendMacro calculations